Press releases

CHEPLAPHARM invests in portfolio of anti-infectives

Greifswald – 16th June 2021 – CHEPLAPHARM invests in a portfolio for the treatment of various infectious diseases from Astellas

 

With the aim for…

Read more  /  pdf

CHEPLAPHARM continues on the road to success

 

Greifswald  – CHEPLAPHARM consistently implements its growth strategy in 2020 and increases turnover by over 30% to € 680 million.

 

 

With the…

Read more  /  pdf

Changes of Management Board per April

 

CHEPLAPHARM is delighted to announce an addition to its board of management.

With effect of April 1st, 2021 Dr. Keyarasch “Kia” Parssanedjad, M.D.…

Read more  /  pdf

Changes of CHEPLAPHARM Management Board per March

 

Greifswald – 1st March 2021

 

CHEPLAPHARM is delighted to herewith inform of the change of its board of management.

With effect as of 1st of March…

Read more  /  pdf

CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents

 

CHEPLAPHARM Arzneimittel GmbH

CHEPLAPHARM Arzneimittel GmbH Announces Receipt of Required Consents in Connection with the
Consent Solicitation…

Read more  /  pdf

CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation

 

CHEPLAPHARM Arzneimittel GmbH

CHEPLAPHARM Arzneimittel GmbH Announces Consent Solicitation Relating to its

3.500% Senior Secured Notes due 2027

Read more  /  pdf

CHEPLAPHARM acquires rights to Rivotril®

 

Greifswald, 01/11/2021 - CHEPLAPHARM expanded its portfolio by acquiring the commercial rights for Rivotril® from Roche.

 

 

"As a successful start…

Read more  /  pdf

CHEPLAPHARM completes it´s largest acquisition so far

 

Greifswald, 01/05/2021 - CHEPLAPHARM successfully closes acquisition of cardiovascular and metabolic portfolio from Takeda

 

Last week CHEPLAPHARM…

Read more  /  pdf

CHEPLAPHARM acquires rights to Atacand® in more than 70 markets

 

Greifswald, 01/04/2021 - Cheplapharm acquires the global rights for the products Atacand® and Atacand® Plus

 

CHEPLAPHARM has held the rights for…

Read more  /  pdf